Nintedanib
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Using the evidence pack (NINTEDANIB, DB09079), here is the repurposing evaluation report. Note upfront: original_moa, original_indications, and all safety fields are explicitly marked as data gaps in the pack, so I have not fabricated values for them — this is called out where relevant rather than guessed.
Nintedanib: From Angiokinase Inhibition to a New Role in Dermatofibrosarcoma Protuberans
(Original approved indication is not populated in this evidence pack — see Data Gaps below. Nintedanib is presented here by its known pharmacological class, a triple angiokinase inhibitor, pending confirmation of its labeled indication.)
One-Sentence Summary
Nintedanib's original approved indication is not documented in the current evidence pack (data gap). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), based on its known activity as a VEGFR/FGFR/PDGFR-targeting tyrosine kinase inhibitor. This direction is currently supported by 0 clinical trials and 1 review publication — evidence is mechanistic/theoretical only, not yet clinically tested.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not documented in evidence pack (data gap — DrugBank/TFDA license extraction pending) |
| Predicted New Indication | Dermatofibrosarcoma Protuberans |
| TxGNN Prediction Score | 99.15% |
| Evidence Level | L4 |
| New Zealand Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data (original_moa) is not available as a standalone field. However, the repurposing rationale in this evidence pack describes nintedanib as a triple angiokinase inhibitor, with activity against VEGFR, FGFR, and PDGFR. This is consistent with its known public profile as a multi-target tyrosine kinase inhibitor.
Dermatofibrosarcoma protuberans (DFSP) is a rare soft-tissue sarcoma with a well-characterized molecular driver: the COL1A1-PDGFB gene fusion, which causes constitutive activation of PDGFRβ signaling and drives tumor growth. This mechanism is already clinically validated — imatinib, a PDGFR-targeted tyrosine kinase inhibitor, is an approved treatment for DFSP. Since nintedanib's PDGFR-inhibitory activity overlaps directly with this validated disease mechanism, there is a plausible biological rationale for its potential efficacy in DFSP.
That said, the supporting evidence in this pack is limited to a single review article discussing PDGFR inhibitors as a drug class in oncology — it does not report primary data on nintedanib specifically in DFSP, nor is there any clinical trial evidence. The mechanistic logic is sound, but the evidence strength remains indirect (class-level, not drug-specific).
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29408302 | 2018 | Review | Pharmacological Research | Reviews the role of small-molecule PDGFR inhibitors as a drug class in treating neoplastic disorders driven by PDGF signaling; discusses PDGFR inhibition as a therapeutic strategy relevant to PDGFR-fusion-driven tumors such as DFSP, but does not report nintedanib-specific trial or case data. |
New Zealand Market Information
Nintedanib is currently not marketed in New Zealand under this evidence pack (total_licenses: 0), and no product authorizations are on file. No authorization table can be generated at this time.
Safety Considerations
Please refer to the package insert for safety information. (All safety fields — key warnings, contraindications, and drug interactions — are unpopulated in this evidence pack; DDI query returned "not_found.")
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence level is L4 (mechanistic/class-level rationale only) with a single non-drug-specific review article and zero clinical trials for the lead candidate indication (DFSP). While the PDGFR-mechanism argument is biologically credible given the precedent of imatinib in DFSP, there is no direct evidence — preclinical or clinical — for nintedanib itself in this indication, and core safety/regulatory data for the drug are also missing.
To proceed, the following is needed:
- Confirmed original indication and mechanism of action (DG002 — DrugBank API lookup)
- TFDA/package-insert warnings, contraindications, and DDI data (DG001 — currently Blocking; required before any S1 safety pre-assessment)
- Nintedanib-specific preclinical evidence (e.g., PDGFRβ-fusion cell line or xenograft models) supporting activity in DFSP
- A drug-specific literature or case-report search (current single hit is a general PDGFR-inhibitor class review, not nintedanib-specific)
Note: Additional Lower-Priority Candidate Indications
Two further indications were predicted by TxGNN but currently have no clinical trial or literature evidence at all and are scored L5 (model prediction only):
| Predicted Indication | TxGNN Score | Evidence Level | Recommendation |
|---|---|---|---|
| Liposarcoma | 99.13% | L5 | Hold |
| Ovarian Myxoid Liposarcoma | 99.12% | L5 | Hold |
Both are held pending any supporting mechanistic or clinical data; no action is recommended on these at this time.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.